Kollega is a Finnish digital platform that enables secure, real-time consultation between licensed physicians and other healthcare professionals. The platform features a robust verification system ensuring that only licensed medical professionals gain access, and automated moderation technology that safeguards sensitive patient data and maintains strict compliance with privacy regulations.

​

Kollega has become an important resource within Finland’s healthcare ecosystem and is currently used by approximately 50% of the country’s physician workforce. With its proven technology, GDPR‑compliant architecture, and high level of user trust, Kollega is well positioned for broad expansion across the Nordics and the European market.

​

The platform addresses a growing need in modern healthcare — quick access to peer expertise — which supports better clinical decision-making and improved patient outcomes. Structural trends such as increased subspecialization, shortages of specialist skills, and the rapid digitalization of healthcare create favorable conditions for future growth.

​

Kollega’s current revenue model is based on advertising but also opens the door for alternative models, such as premium services, partnerships with healthcare providers, or the use of anonymized data for research and real‑world evidence.

​

Interested in this opportunity? Contact Håkan Persson for a discussion or download an Executive Summary with additional information here:​​​

​​

​

​

Mucocort’s flagship product, internal project name MO45A, is a first-in-class, biodegradable, mucoadhesive patch engineered for direct application to treat Recurrent Aphthous Stomatitis (RAS).

 

RAS is a highly prevalent condition affecting up to 40% of the global population over a lifetime, yet there are currently no approved prescription therapies. MO45A offers rapid pain relief and accelerated healing through a non-steroidal, drug-free dual mechanism: hygroscopic action (absorbing wound exudate) combined with non-pharmacological antimicrobial and anti-inflammatory effects (suppressing cytokines IL-2 and TNF-α).

 

The product is classified as a Class IIa medical device and is advancing toward CE-marking. Clinical studies are ongoing under ISO 14155, manufacturing has been secured, and patents have been granted in Europe, China, Australia, and Japan, providing protection through 2040.

 

Rather than building its own commercial infrastructure, Mucocort’s shareholders are seeking a full acquisition by a partner with established marketing and distribution capabilities within MedTech, oral care, or consumer health.

 

This represents a unique opportunity to acquire:

• A clinically validated, patent-protected technology,

• Positioned in a $2.65 billion global market with significant unmet need,

• Supported by scalable manufacturing and a clear regulatory path.

 

Interested in this opportunity? An Executive Summary with additional information can be requested here: info@experia.se 

​​

Sesta Terra ("Sixth Land") is a natural resort on the Ligurian coast of Italy. It is located just north of the UNESCO world heritage site Cinque Terre ("Five Lands") . The resort is a popular luxury destination for both Italian and international visitors who require a tourist experience of immersion in nature without sacrificing comfort. A truly unique resort in beautiful Italy.

​

Sesta Terra presents a compelling opportunity for investors seeking exposure to a high-performing hospitality asset with clear pathways for scalable growth and value creation.

 

The shareholder family is interested in selling the company, including all assets, licenses and trademarks, and they have engaged Experia Corporate Finance Advisors as their financial advisor to find a new owner for the company. For more information, contact us at: info@experia.se​​​​​​

Experia, representing a strategic buyer in Continental Europe, is leveraging on an extensive track record in the Dental field when seeking for sizeable dental lab acquisition opportunities in the Nordics, Sweden, Finland, Denmark and Norway. Lab owners are welcome to contact us for a confidential discussion about this opportunity: hakan.persson@experia.se or +46707900111

​

​​

​